Sunday, January 17, 2016

FDA approves Cosentyx for the treatment of ankylosing spondylitis and psoriatic arthritis

›
Analysis from UpdatesPlus-Spondyloarthropathy - Industry's source for market intelligence and monitoring We reported in November tha...
Friday, January 15, 2016

US Patent office rejects Amgen's petition against Humira formulation patents potentially delaying market entry of ABP 501

›
One strategy through which companies have been attempting to gain biosimilar market entry utilizes IPR (In...
Thursday, December 17, 2015

UpdatesPlus Alert: GSK announces positive topline data from Phase 3 sirukumab program

›
Source :  UpdatesPlus-Rheumatoid Arthritis - for a full and in depth analysis of all key developments in rheumatoid arthritis R&D cont...
Wednesday, October 14, 2015

Fourth Phase 3 study reports out for Lilly/Incyte's JAK1/2 inhibitor, baricitinib - RA-BEAM demonstrates superiority over Humira in biologic naive rheumatoid arthritis

›
Getting ready for ACR - do you need live coverage and analysis of key data presentations?  Contact us to initiate your UpdatesPlus-Rheumato...
Sunday, October 11, 2015

BI 655066 alert - Phase 3 psoriasis studies announced as Boehringer reports further impressive Phase 2 data for its IL-23 mAb

›
This exert is from our live coverage of EADV - for comprehensive coverage contact leaddisc@leaddiscovery.co.uk Boehringer presente...
Tuesday, October 06, 2015

Invion's INV102 demonstrates modest increase in smoking cessation but significant potential for harm reduction - opportunities to improve quit rate through biomarker guided Phase 3 selection

›
From UpdatesPlus Addictive Disorders - your source for intelligence from the smoking cessation and drug addiction research and development ...
Friday, October 02, 2015

FDA accepts Sandoz's application for biosimilar Etanercept despite Amgen maintaining Enbrel exclusivity to 2029

›
Sandoz has announced it is seeking approval for all indications included in the Enbrel label The is first time the FDA has acc...